Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients - - Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people...
In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.
The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.
The FDA has accepted for priority review the application for tarlatamab to treat adults with advanced SCLC who have disease progression on or after platinum-based chemotherapy.
CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...